• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nonprofit Calls Pfizer’s Minority Fellowship Program Racially Discriminatory

Nonprofit Calls Pfizer’s Minority Fellowship Program Racially Discriminatory

September 26, 2022

Pfizer’s minority fellowship program is discriminatory toward Whites and Asians, claims the nonprofit Do No Harm, a group of healthcare professionals, policymakers and patients dedicated to protecting healthcare from discriminatory ideology.

The lawsuit, filed in the U.S. District Court of the Southern District of New York on Sept. 15, alleges that Pfizer’s nine-year Breakthrough Fellowship Program, which offers mentorship, internships, employment after undergraduate/graduate education and full master’s program scholarships to Black, Latino and Native American students and early-career colleagues, is illegal on multiple fronts. Not only does it violate the Civil Rights Act, it violates the Affordable Care Act, New York state and New York City law, the group alleged.

Although Pfizer also has the Summer Growth Experience Program, a similar initiative open to applicants of all races, what that program offers “is nowhere as comprehensive as the Fellowship’s investment in and commitment to the Breakthrough fellows, as [it] does not appear to offer opportunities for post-undergraduate/post-graduate employment or scholarship for master’s programs,” the group says.

Do No Harm is asking the court to temporarily block Pfizer from selecting the Fellowship’s 2023 class, enforcing its current racial requirements and running advertising for the program with the current requirements. It also has asked the court to permanently bar Pfizer from “maintaining racially discriminatory eligibility requirements” for the program and requests that the court order Pfizer to instate racially neutral criteria.

In a statement provided to CenterWatch Weekly, Pfizer said that it is aware of the lawsuit and stands behind its program.

“Pfizer is an equal opportunity employer proud of its commitment to diversity, equity and inclusion as we strive to create a diverse workforce that represents the patients and communities we serve,” the company added.

At the time of writing, Pfizer’s website still listed meeting “the program’s goals of increasing the pipeline for Black/African American, Latino/Hispanic and Native Americans” as a requirement.

Read the full complaint here: https://bit.ly/3C1Mt48.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing